Identification of proteins in semen-derived extracellular vesicles that bind to Tat and NF-κB and that may impair HIV replication
Science Signaling · 2025
DOI: 10.1126/scisignal.ado9243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Bryson C Okeoma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, HIV-1, tat Gene Products, Human Immunodeficiency Virus, Virus Replication. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, BLRD VA, NIH HHS.
Abstract (Originalsprache)
Replication of HIV-1 requires the coordinated action of host and viral transcription factors, most critically the viral transactivator Tat and the host nuclear factor κB (NF-κB). This activity is disrupted in infected cells that are cultured with extracellular vesicles (EVs) present in human semen, suggesting that they contain factors that could inform the development of new therapeutics. Here, we explored the contents of semen-derived EVs (SEVs) from uninfected donors and individuals with HIV-1 and identified host proteins that interacted with HIV Tat and the NF-κB subunit p65. Integrative network and pathway enrichment analyses of these complexes revealed associations with an array of biological functions regulating gene expression. Several proteins in SEVs bound to both Tat and NF-κB p65: the scaffolding and cell signaling regulatory protein AKAP9, the G protein signaling regulator ARHGEF28, the epigenetic reader BRD2, the small nuclear RNA processor INTS1, and the transcription elongation inhibitor NELFB. When complexed with p65, NELFB also interacted with HEXIM1, another transcription elongation inhibitor, suggesting that SEVs may inhibit HIV-1 propagation through multiple networks of transcriptional activation and repression. Exploring these data and the underlying mechanisms may inform the development of more effective or more durable therapeutics against HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.
- Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY 11794-8651, USA.
- Meharry Medical College, Meharry Proteomics Core, RCMI Research Capacity Core, School of Medicine, Nashville, TN 37208, USA.
- Department of Internal Medicine, Carver College of Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242-1109, USA.
- Medical Service, Iowa City Veterans Affairs Medical Center, University of Iowa, 604 Highway 6, Iowa City, IA 52246-2208, USA.
- Lovelace Biomedical Institute, Albuquerque, NM 87108-5127, USA.
ORCID-Profile: Bryson C Okeoma, Wasifa Naushad, Ashok Chaudhary, Alessio Noghero, Jack T Stapleton, Chioma M Okeoma
Förderung
- NIDA NIH HHS
- BLRD VA
- NIH HHS
Zitieren
APA
Okeoma, B. C., Kaddour, H., Naushad, W., Paromov, V., Chaudhary, A., Noghero, A., Stapleton, J. T., & Okeoma, C. M. (2025). Identification of proteins in semen-derived extracellular vesicles that bind to Tat and NF-κB and that may impair HIV replication. Science Signaling. https://doi.org/10.1126/scisignal.ado9243
Vancouver
Okeoma BC, Kaddour H, Naushad W, Paromov V, Chaudhary A, Noghero A, et al. Identification of proteins in semen-derived extracellular vesicles that bind to Tat and NF-κB and that may impair HIV replication. Science Signaling. 2025. doi:10.1126/scisignal.ado9243
BibTeX
@article{Okeoma2025,
author = {Okeoma, Bryson C and Kaddour, Hussein and Naushad, Wasifa and Paromov, Victor and Chaudhary, Ashok and Noghero, Alessio and Stapleton, Jack T and Okeoma, Chioma M},
title = {Identification of proteins in semen-derived extracellular vesicles that bind to Tat and NF-κB and that may impair HIV replication},
journal = {Science Signaling},
year = {2025},
doi = {10.1126/scisignal.ado9243}
}
EUVIMED